Citigroup
ADAP

Citigroup’s Adaptimmune Therapeutics ADAP Stock Holding History

Citigroup’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,679
Closed -$348 – 6013
2025
Q3 		$348 Buy
+2,679
New +$368 ﹤0.01% 5732
2023
Q4 		– Sell
-582,275
Closed -$454K – 5678
2023
Q3 		$454K Buy
582,275
+79
+0% +$66 ﹤0.01% 3131
2023
Q2 		$539K Buy
582,196
+580,541
+35,078% +$692K ﹤0.01% 3322
2023
Q1 		$1.8K Sell
1,655
-307
-16% -$476 ﹤0.01% 5101
2022
Q4 		$2.87K Sell
1,962
-4,687
-70% -$7.59K ﹤0.01% 5152
2022
Q3 		$7K Sell
6,649
-24,782
-79% -$45.5K ﹤0.01% 5100
2022
Q2 		$53K Buy
31,431
+9,894
+46% +$17K ﹤0.01% 4511
2022
Q1 		$44K Sell
21,537
-8,512
-28% -$23K ﹤0.01% 4775
2021
Q4 		$113K Sell
30,049
-11,942
-28% -$54.4K ﹤0.01% 4665
2021
Q3 		$217K Sell
41,991
-7,932
-16% -$35.6K ﹤0.01% 4075
2021
Q2 		$213K Sell
49,923
-36,078
-42% -$175K ﹤0.01% 4208
2021
Q1 		$457K Buy
86,001
+37,498
+77% +$215K ﹤0.01% 3516
2020
Q4 		$261K Buy
48,503
+47,441
+4,467% +$258K ﹤0.01% 4779
2020
Q3 		$8K Buy
1,062
+69
+7% +$604 ﹤0.01% 6738
2020
Q2 		$10K Sell
993
-1,189
-54% -$7.47K ﹤0.01% 7035
2020
Q1 		$6K Buy
2,182
+2,162
+10,810% +$7.17K ﹤0.01% 7213
2019
Q4 		$0 Sell
20
-2,164
-99% -$2.31K ﹤0.01% 7647
2019
Q3 		$3K Buy
2,184
+35
+2% +$82 ﹤0.01% 7435
2019
Q2 		$9K Buy
2,149
+1,014
+89% +$4.13K ﹤0.01% 7328
2019
Q1 		$5K Buy
+1,135
New +$5.29K ﹤0.01% 7406
2018
Q4 		– Sell
-6,175
Closed -$84K – 7640
2018
Q3 		$84K Hold
6,175
– – ﹤0.01% 6058
2018
Q2 		$73K Buy
6,175
+5,893
+2,090% +$73.5K ﹤0.01% 5976
2018
Q1 		$3K Sell
282
-1,564
-85% -$13.7K ﹤0.01% 7283
2017
Q4 		$12K Buy
+1,846
New +$14.3K ﹤0.01% 6952
2016
Q2 		– Sell
-1
Closed – – 7042
2016
Q1 		$0 Buy
+1
New +$8 ﹤0.01% 7422
2015
Q4 		– Sell
-5,211
Closed -$62K – 7515
2015
Q3 		$62K Buy
+5,211
New +$73.6K ﹤0.01% 5284

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup's ADAP Position: Q4 2025 in Review

Citigroup sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 2,679 shares — an estimated $348 sold.

Citigroup first reported a position in ADAP in Q3 2015 and held it in 26 quarters. The position peaked at $539K in Q2 2023. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Citigroup reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 2,679 Adaptimmune Therapeutics shares in Q4 2025, an estimated $348.
  • Citigroup first reported a position in Adaptimmune Therapeutics in Q3 2015 and held it in 26 quarters.
  • Citigroup's Adaptimmune Therapeutics position peaked at $539K in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.